\
&
Contact us
This was 6 months ago
LocationGroot-Bijgaarden, BE
This event focuses on how the police and defence sectors manage their procurement within the legal frameworks. Attendees will learn about the practical applications of purchasing rules, the key priorities of these organizations, and the pitfalls to avoid. The event is designed to foster trust and build relationships with buyers in these sectors.
Participants will engage in discussions with notable speakers, including Marcy Huchon from the Federal Police and Sylvia Neirynck from Defence, who will share insights on their respective topics in both French and Dutch. The schedule includes networking sessions, a lunch with courses, and opportunities to meet various procurement officials from both sectors, allowing for the establishment of potential collaborations.
The event will proceed as follows:
Target audience: companies and professionals interested in public procurement|industry representatives|business leaders.
For more information about the event and registration details, visit the event's official page or contact the organizers directly.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.